E
Can-Fite BioPharma Ltd.
CANF
$1.45
$0.042.84%
E
Sell
3/14/2023Downgrade
Can-Fite BioPharma Ltd. (CANF) was downgraded to E+ from D- on 3/14/2023 due to a decline in the total return index.
Can-Fite BioPharma Ltd. (CANF) was downgraded to E+ from D- on 3/14/2023 due to a decline in the total return index.
D
Sell
2/23/2023Upgraded
Can-Fite BioPharma Ltd. (CANF) was upgraded to D- from E+ on 02/23/2023.
Can-Fite BioPharma Ltd. (CANF) was upgraded to D- from E+ on 02/23/2023.
E
Sell
2/8/2023Downgrade
Can-Fite BioPharma Ltd. (CANF) was downgraded to E+ from D- on 2/8/2023 due to a decline in the growth index, volatility index and total return index. EBIT declined 24.3% from -$2.07M to -$2.57M, and earnings per share declined from -$0.0027 to -$0.0031.
Can-Fite BioPharma Ltd. (CANF) was downgraded to E+ from D- on 2/8/2023 due to a decline in the growth index, volatility index and total return index. EBIT declined 24.3% from -$2.07M to -$2.57M, and earnings per share declined from -$0.0027 to -$0.0031.
D
Sell
1/31/2023Downgrade
Can-Fite BioPharma Ltd. (CANF) was downgraded to D- from D on 1/31/2023 due to a decline in the volatility index and total return index.
Can-Fite BioPharma Ltd. (CANF) was downgraded to D- from D on 1/31/2023 due to a decline in the volatility index and total return index.
D
Sell
1/11/2023Upgraded
Can-Fite BioPharma Ltd. (CANF) was upgraded to D from D- on 1/11/2023 due to an increase in the volatility index.
Can-Fite BioPharma Ltd. (CANF) was upgraded to D from D- on 1/11/2023 due to an increase in the volatility index.
D
Sell
12/23/2022Downgrade
Can-Fite BioPharma Ltd. (CANF) was downgraded to D- from D on 12/23/2022 due to a decline in the volatility index and total return index.
Can-Fite BioPharma Ltd. (CANF) was downgraded to D- from D on 12/23/2022 due to a decline in the volatility index and total return index.
D
Sell
12/8/2022Upgraded
Can-Fite BioPharma Ltd. (CANF) was upgraded to D from D- on 12/8/2022 due to an increase in the growth index.
Can-Fite BioPharma Ltd. (CANF) was upgraded to D from D- on 12/8/2022 due to an increase in the growth index.
D
Sell
11/23/2022Downgrade
Can-Fite BioPharma Ltd. (CANF) was downgraded to D- from D on 11/23/2022 due to a decline in the volatility index and total return index.
Can-Fite BioPharma Ltd. (CANF) was downgraded to D- from D on 11/23/2022 due to a decline in the volatility index and total return index.
D
Sell
11/4/2022Upgraded
Can-Fite BioPharma Ltd. (CANF) was upgraded to D from D- on 11/4/2022 due to an increase in the volatility index.
Can-Fite BioPharma Ltd. (CANF) was upgraded to D from D- on 11/4/2022 due to an increase in the volatility index.
D
Sell
10/19/2022Downgrade
Can-Fite BioPharma Ltd. (CANF) was downgraded to D- from D on 10/19/2022 due to a decline in the volatility index and total return index.
Can-Fite BioPharma Ltd. (CANF) was downgraded to D- from D on 10/19/2022 due to a decline in the volatility index and total return index.
D
Sell
9/30/2022Upgraded
Can-Fite BioPharma Ltd. (CANF) was upgraded to D from D- on 9/30/2022 due to an increase in the volatility index and valuation index.
Can-Fite BioPharma Ltd. (CANF) was upgraded to D from D- on 9/30/2022 due to an increase in the volatility index and valuation index.
D
Sell
9/14/2022Downgrade
Can-Fite BioPharma Ltd. (CANF) was downgraded to D- from D on 9/14/2022 due to a decline in the volatility index.
Can-Fite BioPharma Ltd. (CANF) was downgraded to D- from D on 9/14/2022 due to a decline in the volatility index.
D
Sell
8/29/2022Upgraded
Can-Fite BioPharma Ltd. (CANF) was upgraded to D from D- on 8/29/2022 due to an increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.0101 to -$0.0027, and EBIT increased 48.61% from -$4.03M to -$2.07M.
Can-Fite BioPharma Ltd. (CANF) was upgraded to D from D- on 8/29/2022 due to an increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.0101 to -$0.0027, and EBIT increased 48.61% from -$4.03M to -$2.07M.
D
Sell
5/5/2022Upgraded
Can-Fite BioPharma Ltd. (CANF) was upgraded to D- from E+ on 5/5/2022 due to an increase in the valuation index.
Can-Fite BioPharma Ltd. (CANF) was upgraded to D- from E+ on 5/5/2022 due to an increase in the valuation index.
E
Sell
4/20/2022Downgrade
Can-Fite BioPharma Ltd. (CANF) was downgraded to E+ from D- on 4/20/2022 due to a decline in the volatility index and valuation index.
Can-Fite BioPharma Ltd. (CANF) was downgraded to E+ from D- on 4/20/2022 due to a decline in the volatility index and valuation index.
D
Sell
3/25/2022Downgrade
Can-Fite BioPharma Ltd. (CANF) was downgraded to D- from D on 3/25/2022 due to a large decline in the growth index, total return index and volatility index. Earnings per share declined from -$0.0062 to -$0.0101, EBIT declined 28.57% from -$3.13M to -$4.03M, and total revenue declined 18.4% from $250 to $204.
Can-Fite BioPharma Ltd. (CANF) was downgraded to D- from D on 3/25/2022 due to a large decline in the growth index, total return index and volatility index. Earnings per share declined from -$0.0062 to -$0.0101, EBIT declined 28.57% from -$3.13M to -$4.03M, and total revenue declined 18.4% from $250 to $204.
D
Sell
11/9/2021Upgraded
Can-Fite BioPharma Ltd. (CANF) was upgraded to D from E+ on 11/09/2021.
Can-Fite BioPharma Ltd. (CANF) was upgraded to D from E+ on 11/09/2021.
E
Sell
11/8/2021Downgrade
Can-Fite BioPharma Ltd. (CANF) was downgraded to E+ from D on 11/8/2021 due to a decline in the total return index, solvency index and valuation index. The quick ratio declined from 6.59 to 4.05.
Can-Fite BioPharma Ltd. (CANF) was downgraded to E+ from D on 11/8/2021 due to a decline in the total return index, solvency index and valuation index. The quick ratio declined from 6.59 to 4.05.
D
Sell
3/15/2021Upgraded
Can-Fite BioPharma Ltd. (CANF) was upgraded to D from D- on 3/15/2021 due to an increase in the volatility index, total return index and valuation index.
Can-Fite BioPharma Ltd. (CANF) was upgraded to D from D- on 3/15/2021 due to an increase in the volatility index, total return index and valuation index.
D
Sell
2/26/2021Downgrade
Can-Fite BioPharma Ltd. (CANF) was downgraded to D- from D on 2/26/2021 due to a decline in the volatility index and valuation index.
Can-Fite BioPharma Ltd. (CANF) was downgraded to D- from D on 2/26/2021 due to a decline in the volatility index and valuation index.
D
Sell
2/8/2021Upgraded
Can-Fite BioPharma Ltd. (CANF) was upgraded to D from D- on 2/8/2021 due to a noticeable increase in the solvency index, total return index and volatility index. The quick ratio increased from 0.85 to 8.46, and debt to equity declined from 0.04 to 0.
Can-Fite BioPharma Ltd. (CANF) was upgraded to D from D- on 2/8/2021 due to a noticeable increase in the solvency index, total return index and volatility index. The quick ratio increased from 0.85 to 8.46, and debt to equity declined from 0.04 to 0.
D
Sell
5/1/2020Upgraded
Can-Fite BioPharma Ltd. (CANF) was upgraded to D- from E+ on 5/1/2020 due to an increase in the volatility index.
Can-Fite BioPharma Ltd. (CANF) was upgraded to D- from E+ on 5/1/2020 due to an increase in the volatility index.
E
Sell
5/1/2019Downgrade
Can-Fite BioPharma Ltd. (CANF) was downgraded to E+ from D- on 5/1/2019 due to a large decline in the growth index, solvency index and total return index. Earnings per share declined from -$0.0313 to -$0.0849, the quick ratio declined from 4.23 to 1.26, and EBIT declined 27.25% from -$1.97M to -$2.5M.
Can-Fite BioPharma Ltd. (CANF) was downgraded to E+ from D- on 5/1/2019 due to a large decline in the growth index, solvency index and total return index. Earnings per share declined from -$0.0313 to -$0.0849, the quick ratio declined from 4.23 to 1.26, and EBIT declined 27.25% from -$1.97M to -$2.5M.
D
Sell
1/3/2019Upgraded
Can-Fite BioPharma Ltd. (CANF) was upgraded to D- from E+ on 1/3/2019 due to an increase in the valuation index.
Can-Fite BioPharma Ltd. (CANF) was upgraded to D- from E+ on 1/3/2019 due to an increase in the valuation index.
E
Sell
12/17/2018Downgrade
Can-Fite BioPharma Ltd. (CANF) was downgraded to E+ from D- on 12/17/2018 due to a decline in the total return index and volatility index.
Can-Fite BioPharma Ltd. (CANF) was downgraded to E+ from D- on 12/17/2018 due to a decline in the total return index and volatility index.
D
Sell
1/25/2018Upgraded
Can-Fite BioPharma Ltd. (CANF) was upgraded to D- from E+ on 1/25/2018 due to an increase in the total return index and volatility index.
Can-Fite BioPharma Ltd. (CANF) was upgraded to D- from E+ on 1/25/2018 due to an increase in the total return index and volatility index.
E
Sell
1/2/2018Downgrade
Can-Fite BioPharma Ltd. (CANF) was downgraded to E+ from D- on 1/2/2018 due to a decline in the valuation index.
Can-Fite BioPharma Ltd. (CANF) was downgraded to E+ from D- on 1/2/2018 due to a decline in the valuation index.
D
Sell
12/18/2017Upgraded
Can-Fite BioPharma Ltd. (CANF) was upgraded to D- from E+ on 12/18/2017 due to a noticeable increase in the growth index, valuation index and solvency index. Total revenue increased 3,000% from $2.4 to $74.4, the quick ratio increased from 3.25 to 6.41, and EBIT increased 36.68% from -$2.75M to -$1.74M.
Can-Fite BioPharma Ltd. (CANF) was upgraded to D- from E+ on 12/18/2017 due to a noticeable increase in the growth index, valuation index and solvency index. Total revenue increased 3,000% from $2.4 to $74.4, the quick ratio increased from 3.25 to 6.41, and EBIT increased 36.68% from -$2.75M to -$1.74M.
E
Sell
5/19/2017Downgrade
Can-Fite BioPharma Ltd. (CANF) was downgraded to E+ from D- on 5/19/2017 due to a decline in the growth index, valuation index and solvency index. Total revenue declined 95.72% from $56.1 to $2.4, the quick ratio declined from 8.62 to 3.25, and earnings per share declined from -$0.0499 to -$0.0671.
Can-Fite BioPharma Ltd. (CANF) was downgraded to E+ from D- on 5/19/2017 due to a decline in the growth index, valuation index and solvency index. Total revenue declined 95.72% from $56.1 to $2.4, the quick ratio declined from 8.62 to 3.25, and earnings per share declined from -$0.0499 to -$0.0671.
D
Sell
11/29/2016Downgrade
Can-Fite BioPharma Ltd. (CANF) was downgraded to D- from D on 11/29/2016 due to a decline in the volatility index, efficiency index and valuation index. Net income declined 564.34% from $305.7 to -$1.42M, and total capital declined 25.37% from $10.46M to $7.81M.
Can-Fite BioPharma Ltd. (CANF) was downgraded to D- from D on 11/29/2016 due to a decline in the volatility index, efficiency index and valuation index. Net income declined 564.34% from $305.7 to -$1.42M, and total capital declined 25.37% from $10.46M to $7.81M.
D
Sell
4/5/2016Upgraded
Can-Fite BioPharma Ltd. (CANF) was upgraded to D from D- on 4/5/2016 due to a large increase in the growth index, valuation index and efficiency index. Net income increased 118.09% from -$1.69M to $305.7, earnings per share increased from -$0.1686 to $0.0222, and total capital increased 108.63% from $5.02M to $10.46M.
Can-Fite BioPharma Ltd. (CANF) was upgraded to D from D- on 4/5/2016 due to a large increase in the growth index, valuation index and efficiency index. Net income increased 118.09% from -$1.69M to $305.7, earnings per share increased from -$0.1686 to $0.0222, and total capital increased 108.63% from $5.02M to $10.46M.
D
Sell
3/11/2016Downgrade
Can-Fite BioPharma Ltd. (CANF) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, total return index and efficiency index. Net income declined 390.85% from -$344.2 to -$1.69M, and total capital declined 20.23% from $6.29M to $5.02M.
Can-Fite BioPharma Ltd. (CANF) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, total return index and efficiency index. Net income declined 390.85% from -$344.2 to -$1.69M, and total capital declined 20.23% from $6.29M to $5.02M.
D
Sell
4/14/2014Upgraded
Can-Fite BioPharma Ltd. (CANF) was upgraded to D from on 4/14/2014 due to a significant increase in the solvency index, volatility index and total return index. The quick ratio increased from 2.19 to 2.81.
Can-Fite BioPharma Ltd. (CANF) was upgraded to D from on 4/14/2014 due to a significant increase in the solvency index, volatility index and total return index. The quick ratio increased from 2.19 to 2.81.
AMEX
04/08/2025 10:41AM Eastern
Quotes delayed
